Actively hiring
Oncology Therapeutics
Drug Discovery
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
Founded in 1997, BioMarin is a global biotechnology company dedicated to transforming lives through genetic discovery. The company develops and commercializes targeted therapies that address the root cause of the genetic conditions that it seeks to treat, helping to better the lives of those struggling with rare genetic disease. BioMarin discoveries have led to eight first or best-in-class commercial treatments and a pipeline of multiple product candidates applying the same science-driven, patient-forward approach to broader group of genetic disorders.
News
BioMarin Pharmaceutical stock holds at $63.94 as analysts stay bullish
BioMarin Pharmaceutical stock closed at $63.94 on September 18, 2026, while J.P. Morgan kept an $86 target. Second-quarter EPS beat estimates by $0.25.
Read more
Report
BioMarin Pharmaceutical stock holds near its 52-week low
BioMarin Pharmaceutical stock closed at USD 63.94 on September 18, 2026, near its USD 60.63 52-week low. J.P. Morgan kept a Buy rating at USD 86.
Read more
Report
What Is Drawing Fresh Attention To BioMarin Pharmaceutical (BMRN)?
BioMarin Pharmaceutical (BMRN) has been in focus after appointing Robert Plenge, M.D., Ph.D., to its Board and Science and Technology Committee, sharpening attention on how governance aligns with the rare-disease portfolio. Recent trading has been choppy
Read more
Report
BioMarin Targets Amicus Synergies as VOXZOGO Nears $1B Milestone
Key Points Interested in BioMarin Pharmaceutical Inc.? Here are five stocks we like better. Amicus integration is advancing: BioMarin expects $200 million in annual non-GAAP cost savings, with most…
Read more
Report
BioMarin Pharmaceutical Adds Independent Director to Board
Detailed price information for Biomarin Pharmaceuticals (BMRN-Q) from The Globe and Mail including charting and trades.
Read more
Report
BioMarin Pharmaceutical Inc. Announces Appointment of Robert Plenge to its Board of Directors, Effective September 10, 2026
Read more
Report
Making Space for Jacob's Big Dreams, Rooted in Family Support
The post Making Space for Jacob's Big Dreams, Rooted in Family Support appeared first on BioMarin.
Read more
Report
Bringing Science Full Circle: Ben Schooler Shares What Has Motivated His Path at BioMarin
The post Bringing Science Full Circle: Ben Schooler Shares What Has Motivated His Path at BioMarin appeared first on BioMarin.
Read more
Report
Cristin Hubbard Reflects on a Career Spent Bringing Innovation to Patients - and Why Working at BioMarin Has Her More Energized Than Ever
The post Cristin Hubbard Reflects on a Career Spent Bringing Innovation to Patients - and Why Working at BioMarin Has Her More Energized Than Ever appeared first on BioMarin.
Read more
Report
Show more news
Growth
Hiring Momentum
73/100
Growing
Open positions
5
5 opened / 0 closed in 30 days
Hiring Dynamics
+100%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Marketing
80% ▲
Management
20% ▲
Actively hiring for Marketing (+4 in 30 days)
Offices
Where the company hires and what each office is for
Cities
2
Hiring now
0
Countries
2
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
São Paulo
Brazil
Regional office
Intercontinental Region
Rua James Joule, 92 – 4o Andar, Sao Paulo, Brazil 04576-080
Istanbul
Turkey
Regional office
Türkiye
Istanbul, Türkiye 34805
